CESVONO
DEAD

Serial Number

90271697

Owner

BRISTOL-MYERS SQUIBB COMPANY

Attorney

Marilyn F. Kelly

Filing Date

Oct 22, 2020

Add to watchlist:

No watchlists yet
View on USPTO

CESVONO Trademark

Serial Number: 90271697

CESVONO is a trademark filed by BRISTOL-MYERS SQUIBB COMPANY on October 22, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

BRISTOL-MYERS SQUIBB COMPANY (4,799 trademarks)

NEW YORK, NY 10154

Entity Type: 03

Trademark Details

Filing Date

October 22, 2020

Registration Date

Not Registered

Published for Opposition

September 14, 2021

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for use in disease testing

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jun 13, 2022 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jun 13, 2022 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 9, 2021 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 14, 2021 NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 14, 2021 NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 14, 2021 NPUB
PUBLISHED FOR OPPOSITION
Sep 14, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 26, 2021 NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 26, 2021 NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 26, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 6, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 6, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 6, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 6, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 6, 2021 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 28, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 27, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 27, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 29, 2021 GNRN
NON-FINAL ACTION E-MAILED
Jan 29, 2021 GNRT
NON-FINAL ACTION WRITTEN
Jan 29, 2021 CNRT
ASSIGNED TO EXAMINER
Jan 27, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 10, 2020 NWOS
NEW APPLICATION ENTERED
Oct 26, 2020 NWAP